Current insights suggest gabapentin-induced neurodegeneration
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262888Keywords:
Antiepileptic drugs, Neurodegenerative disorders, Gabapentin drug, Epilepsy, Cognitive impairment, Neurological effectsAbstract
Antiepileptic drugs (AEDs) are commonly prescribed to treat epilepsy and other neurodegenerative disorders (NDs). Gabapentin (GBP) is a newer, off-label antiepileptic/anticonvulsant for NDs that remains underexplored. Recent evidence indicates that prolonged, frequent, and high-dose use of GBP may be associated with an increased risk of various types of dementia and cognitive impairment. GBP has become 1 of the top 20 most prescribed drugs for NDs. GBP modulates voltage-gated calcium channels by binding to the alpha2delta subunit. One possible mechanism is oxidative stress, which can damage neuronal structures, impair synaptic function, and cause mitochondrial dysfunction, all of which are strongly implicated in the pathogenesis of several NDs and contribute to cognitive decline. Another factor is excitotoxicity, where abnormal glutamatergic activity causes excessive calcium influx and neuronal injury, thereby exacerbating mood problems and memory deficits. Long-term use of GBP interferes with SIRT1 (neuroprotective), CaMKII (calcium regulator), and tau phosphorylation regulation, damaging downstream signalling, disrupting central pain pathways in the spinal cord and brain (central sensitisation), damaging neuronal survival pathways, and promoting neurodegeneration. This literature review aims to synthesise current insights on GBP neurotoxic effects, including changes at the gene and protein levels, neuronal structure, function, and network connectivity, as well as strategies for managing GBP-associated NDs. Further research is needed to clarify the exact mechanisms and to develop protective strategies to reduce neurodegenerative risks, optimise seizure control, and evaluate the risks of GBP in clinical settings.
References
Xia SS, Zerong Y, Xinbo W, Xinbo W, Jinsheng Y, Li N, et al. Long-term gabapentin treatment impairs cognitive function in aged mice via tau hyperphosphorylation. Front Pharmacol. 2025;16:1616775.
Vickers Smith R, Boland EM, Young AM, Lofwall MR, Quiroz A, Staton M, et al. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychol Addict Behav. 2018;32(1):115-21.
Park CM, Inouye SK, Marcantonio ER, Metzger E, Bateman BT, Lie JJ, et al. Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery. JAMA Internal Med. 2022;182(11):1117-27.
Khanam PS, Kannaiah SK. Advances in Machine Learning for Alzheimer’s disease Diagnosis: A Comprehensive Overview and Comparative Analysis. 2024 8th International Conference on Inventive Systems and Control. 2024.
Goa K, Sorkin E. Gabapentin. Drugs. 2012;46:409-27.
Bonnet U, Richter EL, Isbruch K, Scherbaum N. On the addictive power of gabapentinoids: a mini-review. Psychiat Danubina. 2018;30(2):142-9.
Mersfelder TL, Nichols WH. Gabapentin: Abuse, Dependence, and Withdrawal. 2016;50(3):229-33.
Rusciano D. Molecular Mechanisms and Therapeutic Potential of Gabapentin with a Focus on Topical Formulations to Treat Ocular Surface Diseases, Pharmaceuticals. 2024;17(5):623.
Yamamoto H, Hiragami Y, Murayama M, Ishizuka K, Kawahara M, Takashima A. Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in the brain. J Neurochem. 2005;94(5):1438-47.
Hector A, McAnulty C, Piché‐Lemieux ME, Alves‐Pires C. Tau hyperphosphorylation induced by the anaesthetic agent ketamine/xylazine involved the calmodulin‐dependent protein kinase II. FASEB J. 2020;34(2):2968-77.
Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews. Neuroscience. 2016;17(1):5-21.
Varadi G. Mechanism of Analgesia by Gabapentinoid Drugs: Involvement of Modulation of Synaptogenesis and Trafficking of Glutamate-Gated Ion Channels. J Pharmacol Exp Ther. 2024;388(1):121-33.
Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genetic Engineering Biotechnol. 2021;19(1):123.
Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108-13.
Yeşil B, Yurtaslan A. Gabapentin withdrawal in a depressed patient: A case report. Anatolian J Psychiat. 2016;17(3):1.
Rajput HS. Mechanism of Action of Gabapentin. 2025. Available at: https://pharmacyfreak.com/mechanism-of-action-of-gabapentin-2/. Accessed on 17 January 2026.
Kim YK, Jeong-Gill L, Ji-Yeon S, Sung-Moon J, Kyoung-Woon J. The effects of gabapentin pretreatment on brain injury induced by focal cerebral ischemia/reperfusion in the rat. Korean J Anesthesiol. 2010;58(2):184-90.
Shem K, Barncord S, Flavin K, Mohan M. Adverse cognitive effects of gabapentin in individuals with spinal cord injury: preliminary findings. Spinal Cord Ser Cases. 2018;4:9.
Markota M, Morgan RJ. Treatment of Generalised Anxiety Disorder with Gabapentin. Case Rep Psychiat. 2017;6045017.
Yuen ASC, Chen B, Chan AYL, Hayes JF, Osborn DPJ, Besag FMC, et al. Use of gabapentinoid treatment and the risk of self-harm: population-based self-controlled case series study. BMJ. 2025;389:e081627.
Lennox R, Mangin D. Gabapentin misuse. CMAJ. 2019;191(2):E47.
Sheng-En T, Shun-Fa Y, Yu-Hsun W, Chao-Bin Y. Association between gabapentin use and risk of dementia in adults with chronic pain: A nested case-control study. J Affect Disord. 2024;358:205-10.
Kaye AD, Cassagne G, Abbott BM, Dubuisson AM, Fagan JJ, Indovina I, et al. Emerging Clinical Roles of Gabapentin and Adverse Effects, Including Weight Gain, Obesity, Depression, Suicidal Thoughts and Increased Risk of Opioid-Related Overdose and Respiratory Depression: A Narrative Review. Curr Pain Headache Rep. 2025;29:95.
Panebianco M, Al-Bachari S, Weston J, Hutton JL, Marson AG. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2018;10(10):CD001415.
James SWH, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Mol Psychiatry. 2021;27(3):1339-49.
Yakovchik AY, Tolynyova DV, Kashtanova DA, Sutulova ER, Ivanov MV, Mamchur LA, et al. Genetics of psycho-emotional well-being: genome-wide association study and polygenic risk score analysis. 2024;14:1188427.
Kwon Y, Blazyte A, Jeon Y, Kim YJ, An K, Jeon S, et al. Identification of 17 novel epigenetic biomarkers associated with anxiety disorders using differential methylation analysis followed by machine learning based validation. Clin Epigenetics. 2025;17(1):24.
Kuehn BM. Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices. JAMA. 2022;328(13):1283-5.
Schoch KM, DeVos SL, Miller RL, Chun SJ, Michaela N, David FW, et al. Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron. 2016;90(5):941-7.
Rissardo JP, Araujo de Matos UM, Caprara ALF. Gabapentin-Associated Movement Disorders: A Literature Review. Medicines. 2023;10(9):52.
Oh G, Moga DC, Moga DC, Fardo DW, Fardo DW, Abner EL, et al. The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition. 2022;13:910719.
Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse, and diversion: A systematic review. Addiction. 2017;111(7):1160-74.
Chen RJ, Sharma S. GABA Receptor. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026.
Brianna Costales BS, Goodin AJ. Outpatient Off-Label Gabapentin Use for Psychiatric Indications Among U. S. Adults. Psychiatr Serv. 2021;72(11):1246-53.
Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, et al. Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study. Mov Disord. 2020;35(1):176-80.
Taylor CP. Mechanisms of action of gabapentin. Rev Neurol (Paris). 1997:153(1):S39-45.
Li S, Selkoe DJ. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain. J Neurochem. 2020;154(6):583-97.
Raudino F, Valduce-Como O, Mascalzi MG, Zagami A. Gabapentin and Behavioural Disorders in Severe Alzheimer's Disease. J Clin Psychopharmacol. 2004;24(4):459-60.
Mi Z, Povysheva N, Rose ME, Ma J, Zeh DJ, Harikumar N, Bhuiyan, et al. Abolishing UCHL1's hydrolase activity exacerbates ischemia-induced axonal injury and functional deficits in mice. J Cerebral Blood Flow Metabolism. 2024;44(11):1349-61.
Iqbal K, Liu F, Gong CX, Alonso AdelC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica. 2009;118(1):53-69.
Pedicone C, Weitzman SA, Renton AE, Goate AM. Unravelling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases. Mol Neurodegener. 2024;19(1):43.
Amudha S, Babu A. Review about Gabapentin Misuse, Interactions, Contraindications and Side Effects. JCHR. 2025;15(1):303-9.
Quintero GC. Review about gabapentin misuse, interactions, contraindications and side effects. J Exp Pharmacol. 2017;9:13-21.
Borowicz-Reutt KK. Effects of Antiarrhythmic Drugs on Antiepileptic Drug Action-A Critical Review of Experimental Findings. Int J Molecular Sci. 2022;23(5):2891.
Bicket MC, Mao J. Chronic Pain in Older Adults. Anesthesiol Clin. 2015;33(3):577-90.
Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008;17(5):405-21.
Olaibi OK, Osuntokun OS, Ijomone OM. Effects of chronic administration of gabapentin and carbamazepine on the histomorphology of the hippocampus and striatum. Ann Neurosci. 2014;21(2):57-61.
Ghazisaeidi S, Muley MM, Salter MW. Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem. Ann Rev Pharmacol Toxicol. 2023;63:565-83.
Mogil JS, Parisien M, Esfahani SJ, Diatchenko L. Sex differences in mechanisms of pain hypersensitivity. Neurosc Biobehavioral Rev. 2024;163:105749.
El-Kattan MA, Saeed E, Khattab MA, Maksoud F, Eldein ME, Abdel-Roaf NE, et al. Gabapentin-Induced Sub-Chronic Neurotoxicity in Rats and the Protective Role of Alpha-Tocopherol. Gabapentin-Induced Sub-Chronic Neurotoxicity in Rats and the Protective Role of Alpha-Tocopherol. Turk Patoloji Dergisi. 2025;41(3):90-104.
Ozcagli E, Soylemez-Yesilcimen E. P31-30 Gabapentin-Induced Effects on Telomerase Activity and DNA Damage in HEK-293 Cells: An In vitro Study Toxicology Letters. 2025;411:S422.
Zhao D, Baek J, Hume AL, McPhillips EA, Lapane KL. Geographic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States. J Pain Res. 2022;15:443-54.
Downloads
Published
How to Cite
Issue
Section
